Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Extra Pale who wrote (600)	1/24/2002 4:42:18 PM
From: tuck	Read Replies (1) \| Respond to of 1005

EP, What I said. It's intraday recovery surprises me somewhat. Was the knee jerk reaction to sell on the headline and not the body of the PR? Only explanation I have for the wild day. They've got to pay for PIII trials unless they find another partner for it. I have no ideas what the odds of that might be; some BLUE H companies claim to be in talks with multiple pharmas . . . and a year goes by with no deal. My guess is the stock could easily drift back towards the $2s while we and prospective partners await data. Not touching it now. Anyhow, adding PDGM to the WatchList. It has had a wild couple of days, and I've been looking more closely at it as it began to slide noticeably under $5. I might have to listen to the audio archive for details, but its burn rate seems to be in the ballbark of $5 million per quarter. Yahoo! is way off on the cash situation; it should be somewhere near $45 million. This due to a recent financing at $5.50. They have made deals, seem to have some have some interesting niches, and seem to be executing on their deals (i.e. delivered 250 herbicide targets to Bayer). But insider sales bother me. At first, it was mostly early investors and VC bailing. Now high ranking officers are selling, too, at about the price of the recent offering. This suggests to BLUE H manager that a swing trading range of high $3s to $5 is safest for a while. PDGM has its own thread: Subject 51193 The subject post contains the home page link. The site is pretty comprehensive. I would suggest a look at the last quarter PR. I need to do some more figuring, and I am back-logged on conference calls over at Trickle. Busy, busy! Nigel and I would certainly appreciate some help in understanding these guys. They are moving towards a more human approach from an AgBio-centric approach. So maybe nobody here will have that kind of background, but we can hope . . . Cheers, Tuck